Latest Conference Articles

Analyzing copayments and coverage plans for popular weight-loss drugs in the US, researchers addressed the cost-effectiveness of GLP-1 medications for treating obesity.

Three posters showcased at IDWeek 2024 focused on enhancing access to HIV prevention and treatment, as well as increasing uptake of pre-exposure prophylaxis (PrEP) among women.

Multimodal analgesia provides more effective pain management—and leads to a decrease in opioid use.

Researchers explored the overall efficacy of various pediatric vaccines and their effects on antibiotic use, while also addressing vaccine hesitancy among parents.

Suzetrigine could represent the first new nonopioid drug in a distinct class of pain medications in approximately 20 years.

Vaccination against HPV can prevent thousands of cases of cancer each year.

Researchers explored the efficacy of Pfizer-BioNTech’s updated COVID-19 vaccine for the 2023-2024 period and its efficacy in improving various patient outcomes.

Pharmacist management of chronic conditions can lead to improved patient outcomes.

Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.

Cases of meningococcal disease currently exceed prepandemic levels.

Findings from a collection of posters at ACCP underscore the critical role of community pharmacies in promoting health equity and providing high-quality, patient-centered care.

Dozens of presentations at IDWeek 2024 focused on available immunizations, such as those for COVID-19, respiratory syncytial virus, and flu.

Posters presented at ACCP 2024 revealed gaps in pharmacy students’ understanding of off-label drug applications and identified strengths and weaknesses among pharmacy graduates.

Pharmacists can screen for social determinants of health and patient beliefs about medications as a way to improve adherence and subsequent outcomes in heart failure.

The first-line B/F/TAF regiment was evaluated in Hispanic/Latino patients, as well as in those with chronic kidney disease.

Research from ESMO 2024 focused on the relationship between survival outcomes and medication adherence.

Research presented at ACCP 2024 found that addiction medicine consult services could help increase medication for opioid use disorder initiation.

Researchers addressed the prevalence of RSV and its associations with immunization, infection, and hospitalization amongst older adults.

GSK’s respiratory syncytial virus vaccine continued to provide adults aged 60 years and older with clinically meaningful protection.

This year’s annual meeting of the American College of Chest Physicians featured more than 300 educational sessions, insights from over 600 faculty members, and 29.5 hours of CE credits.

Research presented at CHEST 2024 examined outcomes of COVID-19 on patients with alcoholic liver disease, cirrhosis, and non-alcohol steatohepatitis.

Research Presented at CHEST 2024 reported on how mepolizumab can improve asthma control, and reduce exacerbations of concurrent asthma and COPD.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and COPD.

Research being presented at CHEST 2024 analyzed morbidity and outcomes of children infected with influenza, COVID-19 or both.

This year’s meeting will take place from October 6 to 9 in Boston, Massachusetts.

Several posters presented at the Heart Failure Society of America 2024 Annual Meeting looked into the landscape of guideline-directed medical therapy.

In posters presented at the Heart Failure Society of America 2024 Annual Meeting, researchers assessed how substance use disorders impact cardiovascular outcomes.

Among patients with heart failure, researchers aimed to understand the association between social detriments of health and physical frailty.